A single center study in Ottawa, Canada showed that for HR positive, HER2 negative early stage breast cancer patients, oncologists mainly used age (50–64 years), tumor size (10.1–20 mm), and grade (2) for deciding when to order ODX [25]. The gene discussed is ERBB2; the disease is breast carcinoma.